LitCovid-sample-Enju  

PMC:7253482 / 2035-2386 JSONTXT 14 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T310 3-14 NN denotes barriers5,6
T311 14-15 -COMMA- denotes ,
T312 16-21 EX denotes there
T313 22-24 VBZ denotes is
T314 25-27 DT denotes an
T315 28-34 JJ denotes urgent
T316 35-39 NN denotes need
T317 40-43 IN denotes for
T318 44-53 JJ denotes effective
T319 54-69 NNS denotes countermeasures
T320 70-72 TO denotes to
T321 73-79 VB denotes combat
T322 80-85 DT denotes these
T323 86-95 NNS denotes pathogens
T324 97-104 VBG denotes Ongoing
T325 105-112 NN denotes vaccine
T326 113-124 NN denotes development
T327 125-132 NNS denotes efforts
T328 133-138 NN denotes focus
T329 139-141 IN denotes on
T330 142-145 DT denotes the
T331 146-151 NN denotes spike
T332 152-153 -LRB- denotes (
T333 153-154 NN denotes S
T334 154-155 -RRB- denotes )
T335 156-164 NNS denotes proteins
T336 165-169 WDT denotes that
T337 170-178 VBP denotes protrude
T338 179-183 IN denotes from
T339 184-187 DT denotes the
T340 188-193 JJ denotes viral
T341 194-202 NN denotes envelope
T342 203-206 CC denotes and
T343 207-217 VB denotes constitute
T344 218-221 DT denotes the
T345 222-226 JJ denotes main
T346 227-233 NN denotes target
T347 234-236 IN denotes of
T348 237-249 VBG denotes neutralizing
T349 250-263 NN denotes antibodies7,8
T350 265-270 DT denotes These
T351 271-279 JJ denotes trimeric
T352 280-281 NN denotes S
T353 282-290 NNS denotes proteins
T354 291-298 VBP denotes mediate
T355 299-308 JJ denotes host-cell
T356 309-314 NN denotes entry
T357 315-319 IN denotes with
T358 320-323 DT denotes the
T359 324-326 NN denotes S1
T360 327-330 CC denotes and
T361 331-333 NN denotes S2
T362 334-342 NNS denotes subunits
R307 T313 T311 arg1Of is,","
R308 T312 T313 arg1Of there,is
R309 T316 T313 arg2Of need,is
R310 T316 T314 arg1Of need,an
R311 T316 T315 arg1Of need,urgent
R312 T316 T317 arg1Of need,for
R313 T319 T317 arg2Of countermeasures,for
R314 T321 T317 arg3Of combat,for
R315 T319 T318 arg1Of countermeasures,effective
R316 T321 T320 arg1Of combat,to
R317 T319 T321 arg1Of countermeasures,combat
R318 T323 T321 arg2Of pathogens,combat
R319 T323 T322 arg1Of pathogens,these
R320 T328 T324 arg1Of focus,Ongoing
R321 T328 T325 arg1Of focus,vaccine
R322 T328 T326 arg1Of focus,development
R323 T328 T327 arg1Of focus,efforts
R324 T328 T329 arg1Of focus,on
R325 T335 T329 arg2Of proteins,on
R326 T335 T330 arg1Of proteins,the
R327 T335 T331 arg1Of proteins,spike
R328 T335 T332 arg1Of proteins,(
R329 T333 T332 arg2Of S,(
R330 T334 T332 arg3Of ),(
R331 T335 T336 arg1Of proteins,that
R332 T335 T337 arg1Of proteins,protrude
R333 T337 T338 arg1Of protrude,from
R334 T341 T338 arg2Of envelope,from
R335 T341 T339 arg1Of envelope,the
R336 T341 T340 arg1Of envelope,viral
R337 T337 T342 arg1Of protrude,and
R338 T343 T342 arg2Of constitute,and
R339 T335 T343 arg1Of proteins,constitute
R340 T346 T343 arg2Of target,constitute
R341 T346 T344 arg1Of target,the
R342 T346 T345 arg1Of target,main
R343 T346 T347 arg1Of target,of
R344 T348 T347 arg2Of neutralizing,of
R345 T349 T348 arg2Of "antibodies7,8",neutralizing
R346 T353 T350 arg1Of proteins,These
R347 T353 T351 arg1Of proteins,trimeric
R348 T353 T352 arg1Of proteins,S
R349 T353 T354 arg1Of proteins,mediate
R350 T356 T354 arg2Of entry,mediate
R351 T356 T355 arg1Of entry,host-cell
R352 T354 T357 arg1Of mediate,with
R353 T362 T357 arg2Of subunits,with
R354 T362 T358 arg1Of subunits,the
R355 T362 T359 arg1Of subunits,S1
R356 T359 T360 arg1Of S1,and
R357 T361 T360 arg2Of S2,and
R358 T362 T361 arg1Of subunits,S2